Parag Vaidya

Experience

• 

  IBM

  Jan 2013 - Jul 2015

  Based out of Ahmedabad, I worked extensively with a large Indian conglomerate on a Business Transformation Project with the objective to create a process centric culture across the group while increasing efficiency in the utilization of assets, both physical and personnel. Hired under IBM's flagship young leaders program - Consulting By Degrees (CbD) Program. During my tenure, focused on Strategy Consulting in Finance & Costing domains.

  • Consultant - Strategy

    Jul 2014 - Jul 2015

  • Associate Consultant - Strategy

    Jan 2013 - Jun 2014
• 

  Larsen & Toubro

  Aug 2016 - Jul 2019

  A. Manager - EA to Group CFO

  Recruited under L&T's Young Leadership Development Program, this role involved working closely with the Group CFO and aiding him in the process of achieving the objectives set out by the board of directors for the Finance functionKey day-to-day activities include:1. Group Performance Management - Board Presentations & Financial & Credit Analysis2. Capital Budgeting & Real Options3. Financial Modelling (with MS Excel)4. Macro Economic Analysis.

• 

  Guild Capital

  Aug 2019 - Jul 2020

  Led Finance and Due Diligence at Guild Capital - an early-stage venture capital firm. Guild typically backs founders as their first institutional investor, actively partnering with them to assist in crafting growth strategies, architecting high-performance teams, creating distinctive brands, and embracing metric-driven management. As a team, we were responsible for the following:1. Identifying & evaluating new opportunities, deal diligence, and execution (US and India)2. Portfolio Management3. Investor Relations 4. Internal Finance & Accounts Show less

  • Associate

    Feb 2020 - Jul 2020

  • Junior Associate

    Aug 2019 - Jan 2020
• 

  KOIS

  Jun 2020 - now

  At KOIS, we combine blended finance, and investment management to scale businesses and projects with high societal and environmental impact, while offering attractive financial returns. I lead Finance globally for KOIS, and lead the India office for both our practice areas.

  • Associate Partner & CFO

    Jan 2023 - now

  • Chief Financial Officer

    Jun 2020 - Jan 2023
• 

  Medical Learning Hub

  Jul 2022 - now

  Board Member

  Medical Learning Hub (MLH) is a Med-EdTech marketplace platform that enables healthcare professionals (HCPs) to search, book and access trainings. The ambition is to increase learning opportunities for HCPs, maximize experience sharing and bridge the knowledge gaps that exist in various specialties, bridge knowledge gaps, globally. MLH enables all training types: on-site events that are face-to-face or even hands-on, online training at each learner’s own pace, live video classroom sessions, conferences, surgery demos, trainings that are free or at a cost, with or without CME / CPD points, certificate-driven or self-learning, trainings for private audiences, and customized experiences as per program requirements. Show less

• 

  Ambercycle

  Oct 2023 - now

  Board Member

  Every year, over 120 billion garments are disposed of, and less than 1% of textiles get recycled at their end of life. The $2T textile industry lacks modern solutions to adapt to the circular economy - raison d'être for Ambercyle. Ambercycle is a material science company founded in 2015 to create a world where every garment is regenerated. It is developing and scaling a breakthrough technology to manufacture materials and fibers from old clothes, without a sacrifice in quality, rather than from petroleum or new agriculture resources. Using technology, Ambercyle is fundamentally changing the fashion industry and building the infinite textile ecosystem. Show less

• 

  ANeuroTech

  Nov 2023 - now

  Board Observer

  ANeuroTech is committed to bring an effective treatment for people that continue to suffer from depression with associated subjective cognitive problems. It is developing its late stage Phase III drug ANT01 in Partial Responsive Depression (PRD). ANT01 is an once daily, orally-administered small molecule to attack Subjective Cognitive Decline and Potentiate Initial Antidepressant Therapies.